BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Biodexa Pharmaceuticals Plc
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 27, 2026
$0.39−0.07 (-14.36%)
Close on Oct 19, 2026
Biodexa Pharmaceuticals statistics
Financials through Jun 30, 2026, price-based ratios appear once a share price is available
Valuation
| Market Cap | £666.75K |
|---|---|
| Enterprise Value | -£2.56M |
Income (trailing twelve months)
| Operating Income | -£8.65M |
|---|---|
| Pretax Income | -£6.49M |
| EBITDA | -£8.65M |
| EPS (Diluted) | -0.00 GBP |
Returns
| Return on Capital Employed (ROCE) | -86.9% |
|---|
Balance sheet
| Cash & Short-Term Investments | £3.23M |
|---|---|
| Net Cash (Debt) | £3.23M |
| Net Cash Per Share | 0.00 GBP |
| Working Capital | £3.91M |
Financial position
| Current Ratio | 2.41 |
|---|---|
| Quick Ratio | 2.22 |
| Interest Coverage | -37.75 |
Cash flow (trailing twelve months)
| Operating Cash Flow | -£5.59M |
|---|---|
| Capital Expenditures | -£2.00K |
| Free Cash Flow | -£5.59M |
| FCF Per Share | -0.00 GBP |
Efficiency
| Employee Count | 12 |
|---|
Dividends and yields
| FCF Yield | -838.8% |
|---|---|
| Buyback Yield | -2062.1% |
| Shareholder Yield | -2062.1% |
Shares
| Shares Outstanding | 225,818,000,000 |
|---|---|
| Shares Change (YoY) | 1007.7% |
| Float | 225,818,000,000 |
| Shares Held by Insiders | 0.00% |
| Shares Held by Institutions | 0.00% |
Taxes
| Income Tax | -£105.00K |
|---|
Scores
| Altman Z-Score | -19.09 |
|---|
Calculated by StockData from Biodexa Pharmaceuticals's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.